Cancer Drug Pulled From the Market Regains FDA Approval

(MedPage Today) — The FDA has once again approved belantamab mafodotin (Blenrep) for multiple myeloma, 3 years after the drug left the market over questions about its efficacy.
A B-cell maturation antigen (BCMA)-targeted drug, belantamab mafodotin…